The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with zero ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Biktarvy is the number one prescribed regimen ... approved for the treatment of HIV-1 infection and PrEP. The strong results increase the probability of lenacapavir’s approval that should ...

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a prescription drug that’s used to treat HIV. This drug can interact with other medications and some ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Biktarvy is Gilead’s once-a-day single tablet ... GILD is evaluating twice-yearly lenacapavir for the prevention of HIV as PrEP. The company recently reported positive data from a second ...

In contrast to currently available daily HIV medications, such as Gilead’s Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg), this new option could offer a long-acting ...